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Background: Aberrantly expressed and constitutively active STAT3 signaling plays a pivotal role in initiation and
progression of human papillomavirus-induced cervical carcinogenesis. However, the underlying mechanism(s)
responsible for pleiotropic effects of STAT3 signaling is poorly understood. In view of emerging regulatory role of
microRNAs, Let-7a and miR-21 that may interact with STAT3 signaling and/or its downstream effectors, present
study was designed in HPV16-positive cervical cancer cells to assess the functional contribution of these miRs in
STAT3 signaling in cervical cancer.
Methods: Functional silencing of STAT3 signaling and HPV16 oncoprotein expression in SiHa cells was done by
STAT3-specific and 16 E6 siRNAs. Pharmacological intervention of STAT3 was done using specific inhibitors like
curcumin and stattic. Loss-of-function study of miR-21 using miR-21 inhibitor and gain-of-function study of let-7a
was done using let-7a mimic in SiHa cells.
Results: Functional silencing of STAT3 signaling in SiHa cells by STAT3-specific siRNA resulted in a dose-dependent
decrease in cellular miR-21 level. Pharmacological intervention of STAT3 using specific inhibitors like curcumin and
Stattic that abrogated STAT3 activation resulted in loss of cellular miR-21 pool. Contrary to this, specific targeting of
miR-21 using miR-21 inhibitor resulted in an increased level of PTEN, a negative regulator of STAT3, and reduced
active pSTAT3 level. Besides miR-21, restoration of cellular Let-7a using chemically synthesized Let-7a mimic reduced
overall STAT3 level. Abrogation of HPV oncoprotein E6 by specific siRNA resulted in increased Let-7a but loss of
miR-21 and a correspondingly reduced pSTAT3/STAT3 and elevated the level of cellular PTEN.
Conclusions: Our results demonstrate existence of a functional loop involving Let-7a, STAT3 and miR-21 which
were found potentially regulated by viral oncoprotein E6. Implications: miR-21 and Let-7a along with STAT3 may
prove useful targets for pharmacological intervention for management of cervical cancer.
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A high level of constitutively active STAT3 is a charac-
teristic feature of many epithelial cell malignancies that
include cervical cancer [1]. Aberrantly expressed and
constitutively active STAT3 signaling plays a pivotal role
in initiation and progression of cervical cancer and con-
trols expression of viral oncogenes, E6 and E7 during
cervical carcinogenesis [2,3]. However, the underlying
mechanism(s) responsible for pleiotropic effects of STAT3
signaling is poorly understood. Active STAT3 has multiple
effects on cellular physiology and oncogenesis through
transcriptional switching of several promoters of genes
associated with malignant transformation [4]. Apart from
a direct transcriptional control, recent studies suggest
STAT3 may exert its oncogenic role through controlling
the expression of microRNA [5]. Involvement of miRNA,
particularly for fine tuning of transcriptional response, has
been documented for almost all major cellular functions
such as cell proliferation, cell differentiation, stress re-
sponse, apoptosis and transcriptional regulation [6]. Accu-
mulating evidence suggests potential involvement of a
small subset of miRNAs in initiation and progression in a
wide range of human cancers including cervical cancer
[7-12]. miRNAs cooperatively function with transcription
factors in the regulation of sets of target genes, allowing
coordinated modulation of gene expression, both tran-
scriptionally and post-transcriptionally. Our recent ob-
servation demonstrate a strong association of elevated
miR-21 expression with active STAT3 and an inverse cor-
relation with level of Let-7a in tumor tissues from cervical
cancer lesions (unpublished data). These observations
prompted us to investigate if an active Let-7a-STAT3-
miR-21 functional signaling loop operates during cervical
carcinogenesis.
Recent reports suggest that miR-21functions as an
oncomiR in human cancers. Inhibition of miR-21 re-
sulted in cell growth inhibition and caspase-dependent
apoptosis in different types of cancer cells [13]. The
gene encoding miR-21 is controlled by an upstream en-
hancer containing two STAT3 binding sites that are
strictly conserved [14]. On the other hand, miR-21 tar-
gets PTEN gene through a binding site on the 3′UTR in
hepatocellular carcinoma [15]. PTEN is a critical tumor
suppressor gene that negatively regulates STAT3 activity
[16]. Nevertheless, there is no evidence to support that
miR-21 directly interact with STAT3 signaling. More-
over, the correlation, if any, of miR-21 expression with
constitutively active STAT3 in cervical carcinogenesis is
yet to be established. Apart from miR-21, another
miRNA Let-7 was reported to interact with STAT3 sig-
naling. STAT3 3′UTR possesses a strong putative Let-7a
binding site [17]. Interestingly, Let-7a is frequently down-
regulated in many human cancers including tumors of
colon, lung, and breast [18,19], and forced expression ofLet-7 family members were found to suppress cancer cell
growth, both in vitro and in vivo [20]. These studies
suggested a potential tumor suppressive role of Let-7a.
However, how Let-7a is involved in post-transcriptional
regulation of STAT3 needs to be explored further.
With a particular reference to cervical carcinogenesis,
which is caused by infection of high risk-HPVs through
expression of their viral oncoproteins E6 and E7 [21], it
was recently noted that STAT3 signaling plays a func-
tional regulatory role [3] and get controlled by oncopro-
tein E6 [22]. In view of emerging regulatory role of
microRNAs, Let-7a and mR-21 that may interact with
STAT3 signaling and its downstream effectors, present
study was designed in HPV16-positive cervical cancer
cells to assess the functional contribution of these miRs
in STAT3 signaling in cervical cancer. We also studied
the effect of E6 silencing on miR-21 and Let-7a pools in
cervical cancer cells. Results presented in this article
demonstrate for the first time a relation between miR-21
and Let-7a in HPV E6-mediated active STAT3 signaling
in cervical cancer cells.
Methods
Materials
STAT3 or HPV16 E6 siRNAs were procured from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) as pools
containing 3–5 different target-specific 19-25 nt siRNA
to non-overlapping sequences, along with scrambled
siRNA which was used as control. RNAiMax transfec-
tion kit used to make transient siRNA transfection was
procured from Invitrogen (Carlsbad, CA, USA). Commer-
cially available STAT3 inhibitors, Stattic (STAT3 inhibitor
5; Calbiocam, USA) or herbal derivative curcumin or
difurulylmethane (Sigma, St Louis, MO, USA) were dis-
solved in DMSO as stock (20 mM) and diluted in the
medium immediately before use. miR-21 inhibitor and
Let-7a mimic which are RNA oligonucleotides with no-
vel secondary structure that are designed to inhibit and
augment the function of endogenous miRNAs respect-
ively were purchased from Dharmacon (Lafayette, CO,
USA). miR-specific inhibitor and mimic were dissolved
in nuclease-free water prior to use as per manufacturer’s
instructions and were kept in aliquots at −20°C until use.
Specific antibodies to STAT3 and enhanced chemilumi-
niscence (ECL) detection kit were purchased from Santa
Cruz Biotechnology, whereas anti-pSTAT3 (Y705) and
anti-PTEN were procured from BD Pharmingen (BD
Biosciences, San Jose, CA, USA). As claimed by the
manufacturer and subsequently established by us in an
electrophoretic mobility shift assay [2], the anti-STAT3
antibody used in present study specifically detects the
active form of STAT3. Dulbecco’s modified Eagle’s
medium (DMEM) was obtained from Invitrogen, (Life
Technologies CA, USA), fetal calf serum (FCS), MTT
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bromide], penicillin streptomycin solution, were obtained
from Sigma-Aldrich Chemicals (St Louis, MO, USA). All
other reagents were of analytical grades and were pro-
cured from Sigma-Aldrich unless specified.
Cell line
Cervical cancer cell line, SiHa (HPV16-positive) was
procured from ATCC and was maintained in prescribed
culture conditions in DMEM with 10% FCS and 1×
penicillin-streptomycin solution. Cells were cultured and
treated at sub-confluent density (<30% confluence). Cells
were free of mycoplasma as tested by DAPI staining.
Moreover, these cells are positive for HR-HPV16 and are
known to express full length E6 [23]. Technically, these
cells were easier to transfect than other cervical cancer
cells available and thus were used throughout present
study.
MTT assay
The viability of treated cells was examined by MTT assay
on cells using standard procedure routinely followed in
the laboratory [24]. The cells (5000 c/w) were incubated in
triplicate in a 96-well plate in the presence or absence of
indicated test agent in a final volume of 0.1 ml for desired
durations at 37°C. Thereafter, 0.025 ml of MTT solution
was added to each well. After 2 h incubation at 37°C, the
lysis buffer (20% SDS 50% dimethyl formamide) was ad-
ded, the plate was incubated overnight at 37°C for so-
lubilization of formazan crystals. The OD at 570 nm
was measured using a 96 well multi-scanner autoreader
(Biotek, Winooski, USA) with the lysis buffer serving as
blank and wells lacking cells was used for background
subtraction. The percentage of cell viability was calcu-
lated using the following formula:
Percent cell viability ¼ OD of the experiment samples=
OD of the control samples  100
Transient transfection
For STAT3 and HPV16 E6 RNA interference assay or
transfection of miR-21 inhibitor and Let-7a mimic oli-
gos, SiHa cells (2 × 105 c/w for 6-well in 2 ml or 1000 c/w
in 0.1 ml for 96-well plate) were seeded in antibiotics-
free normal growth medium supplemented with 10% FCS
and incubated at 37°C in a CO2 incubator for 18-24 h
until the cells were 30% confluent. Next day, the cells were
transfected using RNAiMax reagent. For each well to be
transfected, RNAi duplex-Lipofectamine RNAiMax com-
plexes were prepared using varying concentrations of
siRNA against STAT3, HPV16 E6 (20-80 nM) or miR-21
inhibitor and Let-7a mimic (0.1 nM-50 nM) according to
the manufacturer’s instructions. Cells were incubated for48 h and photographed in culture prior to their end-point
assay.
Isolation of total RNA and amplification of microRNAs by
real time-PCR (qRT-PCR)
Upon completion of the indicated time period, cultures
were terminated by washing the cells with ice cold PBS,
prior to isolation of the RNA to remove dead or dying
cells that get detached or get loose. Total RNA from
treated and control cells was extracted using mirVana
miRNA isolation kit Ambion (Austin, Texas, USA) as
per the manufacturer’s instructions. microRNAs expres-
sion was checked by using mirVana qRT-PCR kit and
miR-21 and Let-7a-specific primers (Ambion) as per the
kit protocol. PCR was performed using BioRad iCycler
real-time PCR (BioRad, USA). U6 RNA (Ambion) was
used for normalization. Data were expressed as absolute
fold change with respect to control that was calculated
2-ΔΔCt method. Primer sequences used for miR expres-
sion analysis are given in Additional file 1: Table S1.
Isolation of total proteins from cervical cancer cell lines
and immunoblotting
Upon completion of the indicated time period, cultures
were terminated by washing the cells with ice cold PBS,
prior to isolation of total cellular proteins. Total proteins
from cervical cancer cell lines were prepared by the
method described previously [2]. Total cellular proteins
(50 μg/lane) were separated in 8-12% polyacrylamide gel
and electro-transferred on PVDF membrane (Millipore
Corp, USA). The membrane was probed with primary
antibody of interest. These blots were washed, incubated
with HRP-anti-mouse IgG secondary antibodies and vi-
sualized by ECL detection kit (Santa Cruz) and by ex-
posing the blot to KODAK X-Omat films (Kodak, India).
The membranes were re-probed for β-actin expression
as an internal control. The quantitative densitometric
analysis of the bands was performed using AlphaEase
FC version 4.1.0 (AlphaInnotech Corporation, IL, USA).
Normalized fold difference in expression of STAT3/
pSTAT3 and other proteins in each sample was deter-
mined by densitometric analysis of each band in com-
parison to band in untreated culture and normalized for
input by using respective β-actin bands.
Reverse transcription-PCR (RT-PCR) for STAT3 mRNA
expression
Total RNA was isolated from treated cells using mirVana
microRNA isolation kit as described previously and sub-
jected to reverse transcription using Omniscript RT-PCR
kit (Qiagen, Hilden, Germany) to prepare the cDNA as
per manufacturer instructions [2]. Amplification of STAT3
and GAPDH transcripts from the cDNA was performed
as per routine laboratory procedure. Normalized fold
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ple was determined by densitometric analysis of each band
in comparison to band in untreated culture and normal-
ized for input by using respective GAPDH bands.
Statistical analysis
Student’s t-test was employed to analyze the significant
difference between control and treated cells. p value <0.05
was considered significant. SPSS V16 software was used
for all statistical calculations.
Results
Targeting STAT3 expression in cervical cancer cells
abrogates miR-21 expression
To test the STAT3-mediated regulation of miR-21, first
we performed in vitro silencing of STAT3 expression in
cervical cancer cells, SiHa, using siRNA against STAT3.
SiHa cells were transiently transfected with a pool of
STAT3-specific siRNA at 20, 40, and 80 nM concentra-
tions at 48 h. Treated cultures showed altered cell morph-
ology which was accompanied by significant loss of cell
viability at 40nM or higher doses (Figure 1A). Moreover,
when examined for STAT3 protein level, cells remained in
culture were found with decreased level of STAT3 pro-
teins in a dose-dependent manner (Figure 1B). Inhibition
of STAT3 expression was observed at concentrations as
low as 20 nM and was completely abolished at 80 nM.
These effects were STAT3-specific as control siRNA-
treated cells did not lose their viability at similar doses of
scrambled siRNA. To reconfirm that the STAT3 inhibition
is at the transcript level, cDNA prepared from treated cells
were further analyzed by reverse transcriptase PCR. As
shown in Figure 1C, cells treated with STAT3 siRNA
expressed low level of transcripts. Subsequently these cells
were subjected to miR-21 expression analysis to study the
cellular effects of STAT3 silencing. Interestingly, dose of
STAT3 siRNA that abrogated STAT3 expression re-
sulted in a dose-dependent decline of miR-21 expres-
sion in treated-SiHa cells, whereas endogenous level of
house-keeping gene U6 remained unaltered (Figure 1D).
Altogether, decline in cellular STAT3 level were accom-
panied by reduced expression of miR-21 (Figure 1E).
Inhibition of phospho-STAT3 Tyr(705) by curcumin and
Stattic abrogates miR-21 expression
Considering the regulatory role of Tyr(705) phosphoryl-
ation in dimerization, nuclear translocation and DNA-
binding of STAT3 that initiate downstream signaling, we
attempted inhibition of constitutively active STAT3 signal-
ing in cervical cancer cells by blocking STAT3 Tyr(705)
phosphorylation using two different inhibitors, curcumin,
or Stattic. Among these, curcumin, a strong but non-
specific inhibitor of STAT3 phosphotyrosination at Y705
that control STAT3 dimerization, nuclear translocationand subsequent DNA-binding and transactivation; has
been shown to manifest its effect through blocking up-
stream STAT3 signaling [24,25]. On the contrary, Stattic
selectively inhibits the function of the STAT3 SH2 domain
regardless of the STAT3 activation state in vitro and se-
lectively inhibits activation, dimerization, and nuclear
translocation of STAT3 [26]. SiHa cells treated with in-
creasing concentrations of curcumin or Stattic for 24 h
demonstrated reduction in number of cultured cells at
25 μM dose or higher. A proportion of curcumin or
Stattic-treated cells showed morphology of a typical apop-
totic cell and dose-dependent loss of cell viability was evi-
dent from MTT assay (Figure 2A and E). Curcumin and
Stattic-treated cells when examined for pSTAT3(Y705) by
immunoblotting using specific monoclonal antibody that
recognizes only the phosphorylated STAT3 and subse-
quently with STAT3 antibody that detects total STAT3
pool revealed a dose-dependent decline in cellular level of
active pSTAT3 in treated cells. At lower concentrations,
the inhibitory effect was observed specifically on pSTAT3
level whereas the total STAT3 remained unaltered indicat-
ing specific effect of the inhibitors on STAT3 phosphoryl-
ation at low doses only. However, at higher concentrations
of inhibitors, a simultaneous decline in overall STAT3
pool was observed (Figure 2B and F). Treatment of cells at
25 μM Stattic resulted in complete loss of phosphorylation
at the tyrosine residue 705 (Figure 2F). Further, the cells
treated with curcumin or Stattic were analyzed for miR-21
expression by quantitative real time PCR analysis. Curcu-
min or Stattic at doses that specifically blocked STAT3
phosphorylation (upto 25 μM) abrogated miR-21 level
(Figure 2C, D and G, H).
Silencing of miR-21 promotes accumulation of PTEN and
abrogates pSTAT3 level
To assess functional contribution of miR-21 in constitu-
tive activation of STAT3 in cervical cells, we experimen-
tally knocked down the cellular miR-21 using miRIDIAN
microRNA inhibitor specific for miR-21 and checked its
effects on its downstream target and negative regulator of
STAT3 phosphorylation, PTEN. Cells transfected with
miR-21 inhibitor revealed growth inhibition till 20 nM.
However, beyond this concentration this inhibitor was
cytotoxic and cells started showing cellular alterations re-
sembling apoptosis with decline in overall cell numbers
which was confirmed in MTT assay (Figure 3A). qRT-
PCR analysis of total RNA isolated from treated cells
showed loss of cellular miR-21 level with increasing dose
of the inhibitor. At high doses of inhibitor (50 nM), ex-
pression of control miRNA U6 was partially affected
(Figure 3B). Immunoblot analysis of these cells for PTEN
expression revealed a dose-dependent increase in cellular
PTEN pools in miR-21 inhibitor-treated cells. Treated




Figure 1 Effect of targeting STAT3 expression by RNA interference on miR-21 expression. SiHa cells (2 × 105 cells) transiently-transfected
with indicated concentrations of STAT3-specific siRNA for 48 h were examined for viability, STAT3 protein and transcript levels and expression of
miR-21. Scrambled siRNA (Scrl) was used as control. A. Graph showing SiHa cell viability by MTT assay following transient transfection at indicated
doses of STAT3 siRNA. Values are mean ± SD of triplicate cultures with respect to untreated control. *p value <0.05. B & C. Dose-dependent effect
of STAT3-siRNA on STAT3 expression. Cellular proteins (50 μg/lane) isolated from transfected SiHa cells were examined for STAT3 protein expression by
immunoblotting (B). Blots were stripped and re-probed with β-actin antibody as loading control. (C) Representative Ethidium bromide-stained agarose
gel (3%) photograph showing levels of STAT3 transcripts measured by RT-PCR (upper panel) in cDNA derived from STAT3 siRNA-treated SiHa cervical
cells. GAPDH RT-PCR was used as internal control for input RNA (lower panel). M: ΦX 174 HaeIII-digested molecular weight markers; UT-untreated cells.
D & E. Inhibition of STAT3 levels accompanied loss of cellular miR-21 levels. Total miRNA pool isolated from treated SiHa cells was examined for levels
of miR-21 by qRT-PCR as described in ‘Methods’. Level of ubiquitously-expressed microRNA U6 similarly amplified in parallel was used as input control
of miRNA. (D). Specific STAT3 bands were evaluated densitometrically and normalized against untreated control (UT). miR-21 fold change was
calculated with respect to control by 2-ΔΔCt method. Graph showing mean ± SD of the fold change in expression of STAT3 protein, STAT3 transcripts
and miR-21 after STAT3 inhibition in three independent experiments (E). *p value <0.05 compared to untreated cells.
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hance PTEN level (Figure 3C). Treated cells showed
significant increase in PTEN level at 10nM dose but
a further increase in inhibitor dose did not enhance
PTEN level (Figure 3D). Further analysis of miR-21 in-
hibitor treated cells for levels of pSTAT3 and STAT3
revealed a dose-dependent decrease in STAT3 activationwhereas STAT3 expression was only marginally affected
(Figure 3E).
Let-7a negatively regulates STAT3 expression in cervical
cancer cells
In the next part of our study, we assessed whether Let-7a








Figure 2 (See legend on next page.)
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Figure 2 Effect of pharmacological inhibition of constitutively active STAT3 by curcumin or phospho-STAT3 (Y705)-specific inhibitor
stattic on miR-21 expression. SiHa cells (5 × 105 cells/w) seeded overnight were treated with indicated concentrations of curcumin or stattic for
24 h. Cellular proteins of the treated cells were examined for pSTAT3 (Y705), STAT3 and β-actin by immunoblotting or their RNA was checked for
level of miR-21 and U6. Cells were treated in parallel in a 96 well plate to evaluate effect of treatment on cell viability by MTT assay. A & E. Graph
showing cell viability by MTT assay following treatment with indicated doses of curcumin (A) or stattic (E). Values are mean ± SD of triplicate
cultures with respect to untreated control. *p value <0.05. B & F. Dose-dependent effect of curcumin (B) or stattic (F) on levels of pSTAT3 (Y705).
Cellular proteins (50 μg/lane) isolated from SiHa cells were examined first for pSTAT3 expression by immunoblotting, following which the blots
were stripped and re-probed sequentially with STAT3 and β-actin antibodies as control. C, D, G & H. Inhibition of pSTAT3 levels accompanied loss
of cellular miR-21 levels. Total miRNA pool isolated from SiHa cells treated with curcumin (C) or stattic (G) were examined for miR-21 by qRT-PCR.
Expression of U6 similarly amplified in parallel was used as input control. Specific pSTAT3 and STAT3 bands were evaluated densitometrically
and normalized against untreated control (UT). miR-21 fold change was calculated with respect to control by 2-ΔΔCt method. Graph showing
mean ± SD of the fold change in expression of pSTAT3, total STAT3 and miR-21 after inhibition of STAT3 phosphorylation in three independent
experiments (D & H). *p value <0.05 compared to untreated cells.
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very low, we augmented the level by intracellular deliv-
ery of chemically-enhanced Let-7a mimic that functions
as endogenous mature miRNA, by transient transfec-
tion for 48 h. Cells treated with Let-7a mimic did not
show any peculiar change in morphology of the cultured
cells. However, growth of these cells appeared marginally
inhibited which was evident only at higher concentrations
of Let-7a mimic (Figure 4A). Measurement of Let-7a in
treated cells by qRT-PCR revealed a dose-dependent in-
crease in intracellular Let-7a pools in mimic-treated cells
(Figure 4B). Immunoblotting of total proteins from these
treated cells for assessment of STAT3 proteins revealed
a dose-dependent decrease in level of total STAT3
(Figure 4C). Let-7a at doses above 20nM completely
abolished cellular STAT3 level in cervical cells. These
results demonstrated an inverse correlation between
level of Let-7a and STAT3 (Figure 4D).
Blocking HPV16 E6 oncoprotein results in increased
Let-7a, loss of miR-21 expression, loss of active STAT3
with an increase in PTEN level
As viral oncogene E6 of high risk HPVs play a vital role
in tumorigenic transformation of cervical cells, we as-
sessed the effect of HPV16 E6 silencing on expression of
Let-7a, STAT3 and miR-21. SiHa cells transiently trans-
fected with commercially available HPV16 E6 siRNA re-
vealed an E6 transfection-specific growth inhibition and
loss of cell viability in treated cultures (Figure 5A). Im-
munoblotting of proteins from treated cells revealed an
effective silencing of the viral oncoprotein E6 (Figure 5B).
Analysis of cellular miRNA derived from these treated
cells by Let-7a and miR-21 qRT-PCR revealed an in-
crease in cellular Let-7a pool and a corresponding dose-
dependent decline in miR-21 level (Figure 5C and D).
In contrast, control cells treated with scrambled siRNA
failed to show any change in level of Let-7a or miR-21
expression. Thus, HPV16 E6 targeting resulted in a specific
up-regulation of Let-7a and abrogation of miR-21 level
(Figure 5D). E6-transfected cells were further examined forSTAT3 and PTEN levels to establish the existence of a
miR-mediated loop. E6-transfected cells showed strong de-
cline in level of pSTAT3 in dose-dependent manner with
complete loss of pSTAT3 at 80nM of E6 siRNA (Figure 5E).
In addition to loss of tyr phosphorylation there was a
gradual decline in the overall level of STAT3 protein.
Loss of pSTAT3 was accompanied by gain of PTEN
level in E6-siRNA treated cervical cancer cells.
Discussion
In the present study, we examined the role of specific
miRs, miR-21 and Let-7a in aberrantly expressed STAT3
signaling during cervical carcinogenesis. STAT3 was tar-
geted by different experimental approaches i.e. silencing
the expression using specific siRNA, or abrogation of its
Tyr(705) phosphorylation using a broad spectrum in-
hibitor curcumin or a specific rationally-designed small
molecule inhibitor, Stattic. Irrespective of the experimen-
tal strategy, knocking down STAT3 resulted in a dose-
dependent decline in level of miR-21. Indirect inhibition
of miR-21 by targeting STAT3 or its direct inhibition
using specific hairpin inhibitor reduced viability of cervical
cancer cells and resulted in a dose-dependent accumula-
tion of PTEN. On the contrary, when Let-7a pool of the
cells was augmented by intracellular delivery of a stable
chemically-synthesized Let-7a oligonucleotide mimic,
which structurally and functionally resembled endogen-
ous Let-7a, the treated cells showed a sharp decline in
cellular level of STAT3 protein which was Let-7a dose-
dependent. Further, blocking of oncogenic E6 gene ex-
pression in cervical cancer cells by E6-specific siRNA
resulted in an increase in level of Let-7a and correspond-
ing decline in miR-21 which was accompanied by loss of
active STAT3 and increase in PTEN in E6-transfected
SiHa cells.
Blocking of STAT3 expression by siRNA abrogates miR-21
expression
Inhibitory effect of silencing STAT3 signaling on miR-21




Figure 3 Effect of miR-21 silencing on cell viability, on expression of PTEN and active STAT3 level. SiHa cells transiently-transfected with
indicated concentrations of miR-21 – specific inhibitor for 48 h were examined for viability and expression of downstream target PTEN. A. Graph
showing cell viability by MTT assay following transient transfection with miR-21 inhibitor at indicated doses. Values are mean ± SD of triplicate
cultures with respect to untreated control. *p value <0.05. B. Representative gel photograph showing reduced levels of miR-21 in treated cells
(upper panel). Total miRNA pool isolated from treated SiHa cells was examined for miR-21 by qRT-PCR. Expression of U6 similarly amplified in
parallel was used as input control (lower panel). M: ΦX 174 HaeIII-digested molecular weight markers; UT-untreated cells. C & D. Dose-dependent
accumulation of PTEN in cells treated with miR-21 inhibitor. Cellular proteins isolated from treated SiHa cells were examined first for PTEN
expression by immunoblotting, following which the blots were stripped and re-probed with β-actin antibody as loading control (C). Specific PTEN
bands were evaluated densitometrically and normalized against untreated control (UT). miR-21 fold change was calculated with respect to control
by 2-ΔΔCt method. Graph showing mean ± SD of the fold change in expression of miR-21 and PTEN protein after inhibition of miR-21 in three
independent experiments (D). *p value <0.05 compared to untreated cells. E. Concomitant reduction of pSTAT3 by miR-21 inhibitor. Cellular
proteins isolated from treated SiHa cells were examined first for pSTAT3 and STAT3 expression by immunoblotting, following which the blots
were stripped and re-probed with β-actin antibody as loading control.
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of cervical cancer cells. Loss of any of these mediators was
found detrimental and the observations made in the pre-
sent study indicate existence of a positive regulatory loop.
Elevated level of miR-21 has been reported in cervical
cancer and its role as an oncomiR has been established
previously [11,27,28]. However, the reason for elevated
miR-21 in cervical carcinogenesis remained poorly under-
stood. Apparently, miR-21 forms a critical component ofSTAT3-mediated regulatory circuits that link inflamma-
tion to cancer [29]. Though STAT3-mediated transcrip-
tional regulation of miR-21 is possibly through binding
to the promoter [14], the mechanism(s) how miR-21 in-
fluences STAT3 signaling remained unexplored. Inter-
estingly, recent study in an analogous system, enforced
expression of miR-21 triggered STAT3 signaling [30].
Leads obtained from our miR-21 inhibition experiments
demonstrated that miR-21 is involved in a positive
BA
C D
Figure 4 Effect of transiently expressed Let-7a mimic on cellular STAT3 pools. SiHa cells (2 × 105 cells) transiently-transfected with indicated
concentrations of Let-7a mimic for 48 h were examined for viability, intracellular Let-7a and STAT3 expression. A. Graph showing cell viability by
MTT assay following transient transfection with Let-7a mimic at indicated doses. Values are mean ± SD of triplicate cultures with respect to
untreated control. *p value <0.05. B. Representative gel photograph showing increased intracellular levels of Let-7a in treated cells (upper panel).
Total RNA isolated from treated SiHa cells was examined for Let-7a by qRT-PCR. Expression of U6 similarly amplified in parallel was used as input
control (lower panel). M: ΦX 174 HaeIII-digested molecular weight markers; UT-untreated cells. C & D. Dose-dependent effect of transiently-transfected
Let-7a on STAT3 levels. Cellular proteins isolated from Let-7a mimic-treated SiHa cells were examined for levels of STAT3 protein by immunoblotting
(C). Blots were stripped and re-probed with β-actin antibody as loading control. Specific STAT3 bands were evaluated densitometrically and normalized
against untreated control (UT). Let-7a fold change was calculated with respect to control by 2-ΔΔCt method. Graph showing mean ± SD of the fold
change in expression of intracellular Let-7a and STAT3 protein after treatment with Let-7a mimic in three independent experiments (D). *p value <0.05
compared to untreated cells.
Shishodia et al. BMC Cancer 2014, 14:996 Page 9 of 13
http://www.biomedcentral.com/1471-2407/14/996feedback loop through down-regulation of PTEN that
keeps STAT3 activity under control. PTEN is a negative
regulator of STAT3 activation in HPV-infected cells and
possesses pTyr(705) STAT3 phosphatase activity which is
independent of the kinase activity [16]. miR-21 is known
to regulate PTEN expression in hepatocellular carcinoma
[15] and overexpression of miR-21 results in targeting of
cellular PTEN pools in endometrial cancers [31]. It is
likely that STAT3-induced miR-21 contributes to an im-
portant part of positive feedback loop in cervical cancer
cells that keeps various apoptosis-inducing death regula-
tors including PTEN, under control and miR-21 inhibition
alleviates PTEN suppression leading to abrogated STAT3
signaling. Interestingly, STAT3 activation of miR-21 via
PTEN has been described as a part of an epigenetic switch
that links inflammation to cancer [29]. It is expected that
in the absence of dephosphorylation the pSTAT3 remains
active longer and maintain its intracellular pools at high
level. These observations suggest critical role of miR-21 indown regulation of PTEN and maintenance of constitu-
tively active STAT3 signaling.
Let-7a acts as negative regulator of STAT3
Following the intracellular delivery of Let-7a mimic, we
observed silencing of STAT3 expression. However, the
silencing in this case was not manifested by significant
loss of cell viability. The reasons behind such discrepant
results are difficult to explain. Let-7a has contrasting ac-
tions on STAT3 which may be attributed to pleiotropy
and redundancy in action of this miRNA. On the one side,
it down-regulates the expression of STAT3 at mRNA level
[17] and directly inhibits IL-6 expression [32]. On the
other hand, there are reports that indicate involvement
of Let-7a with constitutively active and phosphorylated
STAT3 through NF-2 (neurofibromatosis-2) [33]. Never-
theless, downregulation of Let-7a is observed in cervical
cancer lesions [28]. We observed that STAT3 expression




Figure 5 Effect of targeting HPV16 E6 oncogene on miRs, Let-7a and miR-21 and level of active STAT3. SiHa cells transiently-transfected
with indicated concentrations of HPV16 E6 -specific siRNA for 48 h were examined for viability, expression of Let-7a and miR-21. Scrambled siRNA
(Scrl) was used as control. A. Graph showing cell viability by MTT assay following transient transfection with E6 siRNA at indicated doses. Values
are mean ± SD of triplicate cultures with respect to untreated control. *p value <0.05. B. Dose-dependent effect of E6-siRNA on endogenous
HPV16 E6 levels. Cellular proteins isolated from transfected SiHa cells were examined for HPV16 E6 protein expression by immunoblotting. Blots
were stripped and re-probed with β-actin antibody as loading control. C & D. Targeting of E6 oncoprotein results in elevation of Let-7a levels and
corresponding decline in miR-21.Total miRNA pools isolated from SiHa cells treated with E6-siRNA were examined for Let-7a (upper panel) and
miR-21 (middle panel) by qRT-PCR (C). Expression of U6 similarly amplified in parallel was used as input control (lower panel). M: ΦX 174 HaeIII-
digested molecular weight markers; UT-untreated cells. Specific HPV16 E6 bands were evaluated densitometrically and normalized against
untreated control (UT). Let-7a and miR-21 fold change were calculated with respect to control by 2-ΔΔCt method. Graph showing mean ± SD of
the fold change in expression of HPV16 E6, Let-7a and miR-21 after transient transfection of E6 in three independent experiments (D). *p value <0.05
compared to untreated cells. E. Effect of targeting HPV E6-siRNA on pSTAT3, STAT3 and PTEN expression levels. Cellular proteins (50 μg/lane) isolated
from transfected SiHa cells were examined for expression of indicated proteins by immunoblotting. Blots were stripped and re-probed with β-actin
antibody as loading control.
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of a negative regulation of STAT3 by Let-7a in cervical
cancer cells. Consistent with our observation, restoration
of Let-7 expression has been found associated with reduc-
tion in tumor growth in those cancers in which the Let-7
family is globally decreased [34,35], and a reduced expres-
sion of Let-7a was found associated with poor prognosis
and shortened post-operative survival [19], thus suggestive
of a tumor suppressive role of Let-7a during cervical car-
cinogenesis that may be manifested through control of
aberrant STAT3 signaling.
HPV16 oncoprotein E6 controls STAT3 signaling through
a regulatory circuit mediated by Let-7a, miR-21 and PTEN
Recent studies have illustrated a possible interaction
between HPV oncoprotein E6 and cellular microRNAs
particularly miR-23b, miR-34a and miR-218 [36-38].
However, its effects on miR-21 and Let-7a remained elu-
sive. Our results demonstrate that an E6-specific silen-
cing not only down-regulates miR-21 but also leads to
accumulation of Let-7a. These alterations were associ-
ated with loss of active STAT3, increase in PTEN level
and reduced viability of cervical cancer cells. Silencing
of E6/E7 has been reported to induce growth inhibition,
loss of transformed phenotype, induces apoptosis and
replicative senescence in cervical cancer cells and inhib-
ited tumor formation in animal models [39,40]. Since
knockdown of E6 expression in cervical cells resulted in
loss of STAT3 regulatory circuitry, it is likely that con-
stitutively active STAT3 critically requires expression of
viral oncoprotein to maintain its associated miR pro-
files. During the course of infection, some of the viral
derivatives are known to alter cellular miRNA profiles.
HIV-1 was reported to globally suppress host miRNA
expression [41]. The Epstein-Barr virus latent membrane
protein 1 was reported to activate miRNA-155 transcrip-
tion [42]. Similarly, hepatitis B viral protein, HBx, also
plays a role in deregulating cellular miRNAs in hepato-
cellular carcinoma [17]. Why HPV oncoproteins or other
pathogenic viral infections activate and sustain STAT3 sig-
naling is still unknown. It is likely that active STAT3 is
essential for expression of viral oncogenes. A strong
correlation of active STAT3 with levels of E6/E7 in cer-
vical cancer lesions, and specific silencing of STAT3
resulting in abrogated E6 expression in cervical cancer
have been observed earlier [1,3]. Taken together, these
leads are suggestive of a cooperative interaction bet-
ween HPVE6 and STAT3 signaling that may have a car-
cinogenic outcome.
Interestingly, loss of E6 also translated in accumulation
of Let-7a. In view of the fact that Let-7a is a negative
regulator of STAT3 transcript, loss of E6 and resultant
build-up of Let-7a pool result in a stronger silencing of
STAT3 which is also manifested at the transcript level.Although there is no report that implicate E6 in re-
ducing cellular Let-7a, a decline of Let-7a is frequently
reported in cervical neoplastic tissues [28,43]. Further
studies are needed to understand the inhibitory effect of
E6 on Let-7a. In view of the fact that E6 is known to ac-
tivate IL-6/STAT3 signaling in cervical cancer cells [22],
our results demonstrate existence of HPV16 E6-induced
proinflammatory signaling that operate through STAT3
and miR-21 by blocking its negative regulators Let-7a
and PTEN.
Conclusions
Overall, we demonstrate for the first time, an existence
of miRNA-mediated loop involving miR-21 and Let-7a,
which are positively fed by viral oncoprotein E6 and
responsible for aberrant STAT3 signaling during HPV-
induced cervical carcinogenesis. Therefore, silencing
STAT3 by siRNA, curcumin and Stattic, and targeting
miR-21 by antisense or small-molecule compounds may
represent a potential therapeutic strategy for targeted
treatment of cervical and other cancers which invariably
overexpress STAT3.
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